Palantir’s growing presence in the United Kingdom is facing fresh scrutiny after a cross-party parliamentary committee recommended that the government reconsider one of the company’s most significant public-sector contracts.
The debate centers on Palantir’s £330 million NHS data platform contract, awarded in 2023, and reflects a broader question that governments across Europe are increasingly confronting: how much critical national infrastructure should depend on foreign technology providers?
Why UK Lawmakers Are Concerned
A report released by the UK Parliament’s Science, Innovation and Technology Committee described Palantir as the most concerning technology supplier currently operating within British public services.
The committee argued that the UK risks becoming overly dependent on a single vendor for critical healthcare infrastructure and warned about the dangers of “vendor lock-in” where governments become so reliant on a supplier that switching away becomes difficult, expensive, and operationally disruptive.
The report specifically recommended that the government consider exercising a break clause in Palantir’s NHS contract and begin developing a domestic alternative before the end of 2026.
According to the committee, the concern is not simply about software performance. Instead, lawmakers are questioning whether a foreign company should occupy such a central role in systems that support one of Britain’s most important public institutions.
Questions Around Digital Sovereignty
The committee’s concerns extend beyond healthcare.
Lawmakers also raised questions about a separate £240 million Ministry of Defence contract awarded to Palantir in late 2025. They have requested greater transparency around how the contract was awarded and why a competitive tender process was not used.
At the heart of the discussion is the concept of digital sovereignty, the idea that nations should maintain greater control over the technology systems that power critical services, especially during periods of geopolitical uncertainty.
Committee chair Chi Onwurah argued that excessive dependence on a single supplier creates strategic vulnerabilities and reduces the government’s leverage over time.
According to the report, the government should provide greater clarity regarding the exact nature of patient information that Palantir can access through NHS systems and explain the safeguards in place to protect that data.
Political Concerns Add Fuel to the Debate
Unlike many technology procurement disputes, this controversy is not solely about contracts and software.
The parliamentary report explicitly referenced Palantir’s political associations, including its extensive work with the US military and intelligence agencies, as well as public comments made by CEO Alex Karp and co-founder Peter Thiel.
Lawmakers argued that some of these positions appear inconsistent with British public values and raised concerns about entrusting key national systems to a company whose leadership frequently takes public positions on geopolitical and military issues.
The report described these political differences as a “clear mismatch” with British values, adding another layer to an already sensitive discussion.
Palantir Pushes Back
Palantir has strongly rejected the committee’s conclusions.
Louis Mosley, the company’s UK chief, criticized the report and argued that it focuses more on politics than on practical outcomes.
According to Mosley, the company’s technology is already delivering measurable improvements across the NHS, helping hospitals improve operational efficiency, reduce waiting times, and deliver better patient care.
Palantir says that as of February 2026, 168 NHS hospital trusts had signed up to use its platform, with dozens reporting tangible benefits from the system.
The company also argues that it operates under the same rules and oversight requirements as other government technology providers and that concerns about its role have been overstated.
A Growing Presence in Britain
The timing of the report is significant because Palantir has been steadily expanding its footprint across the UK.
Prime Minister Keir Starmer visited the company’s headquarters during a trip to Washington, highlighting the government’s interest in strengthening technology partnerships.
The company has also committed to investing £1.5 billion in the UK by 2030 and continues to pursue opportunities across healthcare, defense, and public-sector modernization.
The UK has become an increasingly important market for Palantir. In its latest quarter, the company reported approximately $130 million in UK revenue, accounting for roughly 8% of total sales.
What Happens Next?
The parliamentary committee does not have the authority to cancel the NHS contract directly.
However, its recommendations increase pressure on the government to justify its reliance on Palantir and explain how it plans to avoid long-term dependence on a single supplier.
The UK government now has two months to formally respond to the report and address the concerns raised by lawmakers.
For investors, the situation highlights a challenge that may become increasingly common for major technology providers. As software companies move deeper into healthcare, defense, and government operations, debates around sovereignty, security, transparency, and political influence are likely to become just as important as the technology itself.
Palantir’s UK business continues to grow, but the latest parliamentary scrutiny shows that winning government contracts is only one part of the challenge. Maintaining public and political trust may prove equally important in determining how far the company can expand within critical national infrastructure.
This version is written for a discourse/community audience with a conversational flow, clear context, balanced viewpoints, and emphasis on the broader implications for technology, government procurement, and investors.